GlassScriptPhysician profile
Wendy M Buchi
NPI 1356389688
$6,335.99
in general payments reported to CMS, 2019-2025
42 companies · $965 in 2025
The $965 reported for 2025 was more than what 83% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $685 · 2021: $975 · 2022: $901 · 2023: $741 · 2024: $914 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $935.05 | 2019-2023 | Lo Loestrin Fe, Orilissa, Oriahnn |
| Astellas Pharma US INC | $615.17 | 2019-2025 | Veozah |
| Mayne Pharma Commercial LLC | $411.55 | 2021-2025 | |
| Daiichi Sankyo INC. | $365.00 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $318.52 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $270.17 | 2023-2025 | Myfembree |
| Aspira Women'S Health INC | $260.88 | 2021-2024 | Ova1 |
| Exeltis, USA INC. | $206.03 | 2019-2025 | Slynd |
| Pfizer INC. | $185.65 | 2022-2025 | |
| Coopersurgical, INC. | $183.32 | 2019-2025 | Paragard T 380a, Paragard T 380a, Insorb |
| Amgen INC. | $183.10 | 2019-2025 | Evenity, Prolia, Prolia |
| Allergan, INC. | $180.05 | 2019 | |
| Therapeuticsmd, INC. | $175.49 | 2019-2022 | |
| Shield Therapeutics INC | $171.50 | 2022-2025 | |
| Biogen, INC. | $152.11 | 2024-2025 | Zurzuvae |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Buchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.